Search clinical trials for: Valsartan (Diovan)

Total 536 results

Mustafa Kemal University
Novartis Pharmaceuticals

Completed

Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy

Hypertension | Left Ventricular Hypertrophy

Turkey
Wake Forest University Health Sciences
Johns Hopkins University

Terminated

Angiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients (RAS-HIV)

HIV | Sarcopenia | Aging | Angiotensin Receptor Antagonists

United States
Hallym University Medical Center

Unknown

Valsartan Efficacy on Modest Blood Pressure Reduction in Acute Ischemic Stroke (VENTURE)

Acute Ischemic Stroke

Korea, Republic of
Astellas Pharma Inc

Completed

A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Valsartan in Healthy Volunteers

Healthy | Pharmacokinetics of Valsartan

Japan
Samsung Medical Center

Recruiting

Sacubitril/Valsartan Versus Valsartan in Heart Failure With Improved Ejection Fraction (PROSPER-HF)

Heart Failure, Systolic

Korea, Republic of
KVT-Study Group
Yokohama City University; Showa University; Kitasato University; St. Marianna University... and other collaborators

Completed

Kanagawa Valsartan Trial (KVT): Effects of Valsartan on Renal and Cardiovascular Disease

Hypertension | Chronic Kidney Disease

Japan
University of Washington
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Repurposing Valsartan May Protect Against Pulmonary Hypertension (REVAMP-PH)

Pulmonary Arterial Hypertension | Right Ventricular Dysfunction | Right Heart Failure | Pulmonary Vascular Disorder

United States
Duke University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study) (HFN-LIFE)

Heart Failure

United States
LanZhou University

Recruiting

Effect of LCZ696 on Urinary Microalbumin and Pulse Wave Velocity in Perimenopausal Patients With Hypertension

Hypertension

China
University of Zurich
Novartis Pharmaceuticals

Completed

Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction (VASCEND)

Heart Failure

Switzerland
Radboud University Medical Center

Terminated

Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease

Severe Acute Respiratory Syndrome | COVID-19 | COVID | Acute Respiratory Distress Syndrome | SARS-CoV-2

Netherlands
Emory University

Completed

Effect of Valsartan on Carotid Artery Disease

Atherosclerosis | Carotid Artery Diseases

United States
Novartis

Completed

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension

Hypertension

United States
Medical University of Silesia
Polpharma Pharmaceutical Company

Terminated

Valsartan to Prevent Left Ventricle Remodeling in Pacemaker Patients

First Time Dual Chamber Pacemaker Implantation

Poland
University of Pennsylvania

Suspended

Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition

Hypertension | Diabetes Mellitus, Type 2 | Pre-diabetic | Elevated Blood Pressure

United States
State University of New York at Buffalo

Completed

24 Hour Ambulatory Cardiac Oxygen Consumption

Hypertension

United States
EMS

Withdrawn

Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia.

Hypertension | Dyslipidemia
Ohio State University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Active, not recruiting

The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans

Obesity | PreDiabetes | Blood Pressure | Impaired Glucose Tolerance

United States
Novartis Pharmaceuticals

Completed

The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients (TurkuPET)

Heart Failure

Finland
Dexa Medica Group

Completed

Bioequivalence Evaluation of Two Film-Coated Formulations of Valsartan 160 mg

Healthy

Indonesia
Ain Shams University

Completed

Chronopharmacology of Valsartan in Normotensive Subjects

Healthy Normotensive Volunteers

Egypt
Osaka City University

Completed

Prevention of CHOP-induced Chronic Cardiotoxicity

Non-Hodgkin's Lymphoma

Japan
Takeda

Completed

Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension

Essential Hypertension

China
University of Michigan
Novartis Pharmaceuticals

Withdrawn

The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome (SAAVE)

Hypertension | Metabolic Syndrome

United States
Columbia University
Novartis Pharmaceuticals

Terminated

Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease

Diabetic Nephropathy | Focal Segmental Glomerulosclerosis | IgA Nephropathy | Glomerulonephritis, Membranous | Hypertensive Nephrosclerosis | Proteinuric Kidney Disease | Glomerulopathy (Obesity-associated)

United States
Boryung Pharmaceutical Co., Ltd
Asan Medical Center; Chonnam National University Hospital; Seoul National University... and other collaborators

Completed

A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension

Essential Hypertension

Korea, Republic of
Boryung Pharmaceutical Co., Ltd
Asan Medical Center; Ulsan University Hospital; Korea University Anam Hospital; Dong-A University and other collaborators

Completed

A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension (fimasartan)

Hypertension

Korea, Republic of
Boryung Pharmaceutical Co., Ltd
Chonnam National University Hospital; Seoul National University Hospital; Kyungpook... and other collaborators

Completed

A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential Hypertension

Essential Hypertension
Norwegian University of Science and Technology
St. Olavs Hospital; Alesund Hospital; Namsos Hospital; Volvat Medisinsk Senter...

Recruiting

Bariatric Surgery and Pharmacokinetics of Valsartan

Obesity, Morbid

Norway
HealthCore-NERI
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM (VANISH)

Hypertrophic Cardiomyopathy

United States, Canada
JW Pharmaceutical

Completed

Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia (COCTAIL)

Hypertension | Dyslipidemia

Korea, Republic of
LG Life Sciences

Completed

Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia

Hyperlipidemia | Hypertension,

Korea, Republic of
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD

Pediatric Hypertension With or Without CKD

Belgium, Poland, Italy, Germany, Guatemala, France, Hungary, Brazil, Lithuania
Takeda

Completed

Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension

Hypertension

United States, Mexico, Chile, Peru
Vanderbilt University
National Heart, Lung, and Blood Institute (NHLBI); University of Washington

Terminated

Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3

Endothelial Dysfunction | Oxidative Stress

United States
JW Pharmaceutical

Completed

Pharmacokinetic Study of Livalo® Fixed Combination Drug in Healthy Subjects

Hypertension | Hyperlipidemia

Korea, Republic of
Kyoto Prefectural University of Medicine

Completed

Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study)

Stroke | Hypertension | Ischemic Heart Disease | Congestive Heart Failure

Japan
JW Pharmaceutical

Completed

Pharmacokinetic Study of Livalo® Fixed Combination Drug in Healthy Subjects

Hypertension | Hyperlipidemia

Korea, Republic of
Novartis

Completed

Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension

Essential Hypertension
Novartis Pharmaceuticals

Completed

The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction

Hypertension | Diastolic Dysfunction

United States
Takeda

Completed

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

Hypertension

United States, Mexico, Peru, Brazil, Argentina, Puerto Rico
Novartis

Completed

To Demonstrate Non-inferiority of Combination of 5 mg Amlodipine/ 80 mg Valsartan to 160 mg Valsartan Alone

Hypertension | High Blood Pressure

Taiwan
Bayer

Completed

Low-dose Nifedipine-Valsartan Combination Compared to Up-titrated Valsartan Monotherapy in Essential Hypertension

Hypertension

China, Korea, Republic of
AstraZeneca
Bristol-Myers Squibb

Completed

Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects

Type 2 Diabetes Mellitus

United States
Fundación Lindavista del Corazón AC

Terminated

Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168)

Hypertension
Boryung Pharmaceutical Co., Ltd

Completed

Fimasartan Achieving SBP Target (FAST) Study (FAST)

Essential,Hypertension

Korea, Republic of
Qingdao Central Hospital

Not yet recruiting

Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction

Myocardial Infarction | Hypertension

China
Novartis

Completed

Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome (LesScore)

Hypertension, Dyslypidaemia
Eisai Inc.
Eisai Co., Ltd.

Completed

Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension

High Blood Pressure

Taiwan
Peking Union Medical College Hospital

Unknown

Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy (HCQIgAN)

Primary IgA Nephropathy

China

Search clinical trials for: Valsartan (Diovan)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations